CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors

References

• Ponzetta A, Carriero R, Carnevale S, Barbagallo M, Molgora M, Perucchini C, Magrini E, Gianni F, Kunderfranco P, Polentarutti N, et al. Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors. Cell. 2019;178(2):346–60 e24. doi:10.1016/j.cell.2019.05.047.
   PubMed Web of Science ®Google Scholar
• Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 2010;16(2):219–15. doi:10.1038/nm.2084.
   PubMed Web of Science ®Google Scholar
• Butin-Israeli V, Bui TM, Wiesolek HL, Mascarenhas L, Lee JJ, Mehl LC, Knutson KR, Adam SA, Beyder A, Wiesmuller L, et al. Neutrophil-induced genomic instability impedes resolution of inflammation and wound healing. J Clin Invest. 2019;129(2):346–360.e24. doi:10.1172/JCI122085.
   Web of Science ®Google Scholar
• Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J, et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345–348. doi:10.1038/nature14282.
   PubMed Web of Science ®Google Scholar
• Wculek SK, Malanchi I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature. 2015;528(7582):413–417. doi:10.1038/nature16140.
   PubMed Web of Science ®Google Scholar
• Albrengues J, Shields MA, Ng D, Park CG, Ambrico A, Poindexter ME, Upadhyay P, Uyeminami DL, Pommier A, Küttner V, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018;361(6409). doi:10.1126/science.aao4227.
   PubMed Web of Science ®Google Scholar
• Wellenstein MD, Coffelt SB, Duits DEM, van Miltenburg MH, Slagter M, de Rink I, Henneman L, Kas SM, Prekovic S, Hau C-S, et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature. 2019;572(7770):538–542. doi:10.1038/s41586-019-1450-6.
   PubMed Web of Science ®Google Scholar
• Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A. 2006;103(33):12493–12498. doi:10.1073/pnas.0601807103.
   PubMed Web of Science ®Google Scholar
• Albini A, Bruno A, Noonan DM, Mortara L. Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy. Front Immunol. 2018;9:527. doi:10.3389/fimmu.2018.00527.
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69(4):1553–1560. doi:10.1158/0008-5472.CAN-08-1921.
   PubMed Web of Science ®Google Scholar
• Rice CM, Davies LC, Subleski JJ, Maio N, Gonzalez-Cotto M, Andrews C, Patel NL, Palmieri EM, Weiss JM, Lee J-M, et al. Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression. Nat Commun. 2018;9(1):5099. doi:10.1038/s41467-018-07505-2.
   PubMed Web of Science ®Google Scholar
• Veglia F, Tyurin VA, Blasi M, De Leo A, Kossenkov AV, Donthireddy L, To TKJ, Schug Z, Basu S, Wang F, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. 2019;569(7754):73–78. doi:10.1038/s41586-019-1118-2.
   PubMed Web of Science ®Google Scholar
• Glodde N, Bald T, van den Boorn-konijnenberg D, Nakamura K, O’Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, et al. Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy. Immunity. 2017;47(4):789–802 e9. doi:10.1016/j.immuni.2017.09.012.
   PubMed Web of Science ®Google Scholar
• Veglia F, Hashimoto A, Dweep H, Sanseviero E, De Leo A, Tcyganov E, Kossenkov A, Mulligan C, Nam B, Masters G, et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med. 2021;218(4). doi:10.1084/jem.20201803.
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. doi:10.1093/jnci/dju124.
   PubMedGoogle Scholar
• Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945. doi:10.1038/nm.3909.
   PubMed Web of Science ®Google Scholar
• Kargl J, Busch SE, Yang GH, Kim KH, Hanke ML, Metz HE, Hubbard JJ, Lee SM, Madtes DK, McIntosh MW, et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. 2017;8(1):14381. doi:10.1038/ncomms14381.
   PubMed Web of Science ®Google Scholar
• Mitchell KG, Diao L, Karpinets T, Negrao MV, Tran HT, Parra ER, Corsini EM, Reuben A, Federico L, Bernatchez C, et al. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. J Immunother Cancer. 2020;8(1):e000405. doi:10.1136/jitc-2019-000405.
   PubMed Web of Science ®Google Scholar
• Shaul ME, Eyal O, Guglietta S, Aloni P, Zlotnik A, Forkosh E, Levy L, Weber LM, Levin Y, Pomerantz A, et al. Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis. FASEB J. 2020;34(3):4204–4218. doi:10.1096/fj.201902467R.
   PubMed Web of Science ®Google Scholar
• Pore N, Wu S, Standifer N, Jure-Kunkel M, de Los Reyes M, Shrestha Y, Halpin R, Rothstein R, Mulgrew K, Blackmore S, et al. Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in patients with non–small cell lung cancer and is reversed by STAT3 knockdown. Cancer Discov. 2021;11(11):2828–2845. doi:10.1158/2159-8290.CD-20-1543.
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Theron AJ, Vorobiof DA, Langenhoven L, Hall JM, Van Eeden RI, Smit T, Chan S-W, Botha MC, Raats JI, et al. Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer. Lung Cancer Manag. 2020;9(3):LMT37. doi:10.2217/lmt-2020-0014.
   PubMedGoogle Scholar
• Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, Berruti A, Falcone A, Aieta M, Gelibter A, et al. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and outcomes with nivolumab in pretreated Non-Small Cell Lung Cancer (NSCLC): a large retrospective multicenter study. Adv Ther. 2020;37(3):1145–1155. doi:10.1007/s12325-020-01229-w.
   PubMed Web of Science ®Google Scholar
• Jiang T, Bai Y, Zhou F, Li W, Gao G, Su C, Ren S, Chen X, Zhou C. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. Lung Cancer. 2019;130:76–83. doi:10.1016/j.lungcan.2019.02.009.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Mo F, Li Q, Han X, Shi H, Chen S, Wei Y, Wei X. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin. Mol Cancer. 2021;20(1):62. doi:10.1186/s12943-021-01355-1.
   PubMed Web of Science ®Google Scholar
• Germann M, Zangger N, Sauvain MO, Sempoux C, Bowler AD, Wirapati P, Kandalaft LE, Delorenzi M, Tejpar S, Coukos G, et al. Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGF β. EMBO Mol Med. 2020;12(1):e10681. doi:10.15252/emmm.201910681.
   PubMed Web of Science ®Google Scholar
• Engblom C, Pfirschke C, Zilionis R, Da Silva Martins J, Bos SA, Courties G, Rickelt S, Severe N, Baryawno N, Faget J, et al. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecF high neutrophils. Science. 2017;358(6367). doi:10.1126/science.aal5081.
   PubMed Web of Science ®Google Scholar
• Zilionis R, Engblom C, Pfirschke C, Savova V, Zemmour D, Saatcioglu HD, Krishnan I, Maroni G, Meyerovitz CV, Kerwin CM, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 2019;50(5):1317–34 e10. doi:10.1016/j.immuni.2019.03.009.
   PubMed Web of Science ®Google Scholar
• Schenkel JM, Herbst RH, Canner D, Li A, Hillman M, Shanahan SL, Gibbons G, Smith OC, Kim JY, Westcott P, et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1(+) CD8(+) T cells in tumor-draining lymph nodes. Immunity. 2021;54(10):2338–53 e6. doi:10.1016/j.immuni.2021.08.026.
   PubMed Web of Science ®Google Scholar
• Horton BL, Morgan DM, Momin N, Zagorulya M, Torres-Mejia E, Bhandarkar V, Wittrup KD, Love JC, Spranger S. Lack of CD8 + T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer. Sci Immunol. 2021;6(64):eabi8800. doi:10.1126/sciimmunol.abi8800.
   PubMed Web of Science ®Google Scholar
• Li BH, Garstka MA, Li ZF. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. Mol Immunol. 2020;117:219–223. doi:10.1016/j.molimm.2019.11.014.
   Web of Science ®Google Scholar
• Zhou SL, Dai Z, Zhou ZJ, Chen Q, Wang Z, Xiao YS, Hu Z-Q, Huang X-Y, Yang G-H, Shi Y-H, et al. CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils. Carcinogenesis. 2014;35(3):597–605. doi:10.1093/carcin/bgt397.
   PubMed Web of Science ®Google Scholar
• Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang X-W, Fan J, Zhou J. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology. 2012;56(6):2242–2254. doi:10.1002/hep.25907.
   PubMed Web of Science ®Google Scholar
• Soler-Cardona A, Forsthuber A, Lipp K, Ebersberger S, Heinz M, Schossleitner K, Buchberger E, Gröger M, Petzelbauer P, Hoeller C, et al. CXCL5 facilitates melanoma cell-neutrophil interaction and lymph node metastasis. J Invest Dermatol. 2018;138(7):1627–1635. doi:10.1016/j.jid.2018.01.035.
   PubMed Web of Science ®Google Scholar
• Forsthuber A, Lipp K, Andersen L, Ebersberger S, Graña C, Ellmeier W, Petzelbauer P, Lichtenberger BM, Loewe R. CXCL5 as regulator of neutrophil function in cutaneous melanoma. J Invest Dermatol. 2019;139(1):186–194. doi:10.1016/j.jid.2018.07.006.
   PubMed Web of Science ®Google Scholar
• Gao Y, Guan Z, Chen J, Xie H, Yang Z, Fan J, Wang X, Li L. CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9. Int J Oncol. 2015;47(2):690–700. doi:10.3892/ijo.2015.3041.
   PubMed Web of Science ®Google Scholar
• Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian L, Richmond A, Lin PC, et al. Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008;13(1):23–35. doi:10.1016/j.ccr.2007.12.004.
   PubMed Web of Science ®Google Scholar
• Romero-Moreno R, Curtis KJ, Coughlin TR, Miranda-Vergara MC, Dutta S, Natarajan A, Facchine BA, Jackson KM, Nystrom L, Li J, et al. The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis. Nat Commun. 2019;10(1):4404. doi:10.1038/s41467-019-12108-6.
   PubMedGoogle Scholar
• Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, Strieter RM. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med. 1991;174(6):1355–1362. doi:10.1084/jem.174.6.1355.
   PubMed Web of Science ®Google Scholar
• Nouailles G, Dorhoi A, Koch M, Zerrahn J, Weiner J 3rd, Faé KC, Arrey F, Kuhlmann S, Bandermann S, Loewe D, et al. CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. J Clin Invest. 2014;124(3):186–194. doi:10.1172/JCI72030.
   Web of Science ®Google Scholar
• Mei J, Liu Y, Dai N, Favara M, Greene T, Jeyaseelan S, Poncz M, Lee JS, Worthen GS. CXCL5 regulates chemokine scavenging and pulmonary host defense to bacterial infection. Immunity. 2010;33(1):106–117. doi:10.1016/j.immuni.2010.07.009.
   PubMed Web of Science ®Google Scholar
• Saintigny P, Massarelli E, Lin S, Ahn Y-H, Chen Y, Goswami S, Erez B, O’Reilly MS, Liu D, Lee JJ, et al. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res. 2013;73(2):571–582. doi:10.1158/0008-5472.CAN-12-0263.
   PubMed Web of Science ®Google Scholar
• Han N, Yuan X, Wu H, Xu H, Chu Q, Guo M, Yu S, Chen Y, Wu K. DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling. Oncotarget. 2015;6(8):5877–5888. doi:10.18632/oncotarget.3463.
   PubMedGoogle Scholar
• Wang J, Hu T, Wang Q, Chen R, Xie Y, Chang H, Cheng J. Repression of the AURKA-CXCL5 axis induces autophagic cell death and promotes radiosensitivity in non-small-cell lung cancer. Cancer Lett. 2021;509:89–104. doi:10.1016/j.canlet.2021.03.028.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Shurin GV, Zhong H, Bunimovich YL, Han B, Shurin MR. Schwann cells augment cell spreading and metastasis of lung cancer. Cancer Res. 2018;78(20):5927–5939. doi:10.1158/0008-5472.CAN-18-1702.
   PubMed Web of Science ®Google Scholar
• Hu B, Fan H, Lv X, Chen S, Shao Z. Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis. Cancer Cell Int. 2018;18(1):68. doi:10.1186/s12935-018-0562-7.
   PubMedGoogle Scholar
• Wu K, Yu S, Liu Q, Bai X, Zheng X, Wu K. The clinical significance of CXCL5 in non-small cell lung cancer. Onco Targets Ther. 2017;10:5561–5573. doi:10.2147/OTT.S148772.
   PubMed Web of Science ®Google Scholar
• Mollaoglu G, Jones A, Wait SJ, Mukhopadhyay A, Jeong S, Arya R, Camolotto SA, Mosbruger TL, Stubben CJ, Conley CJ, et al. The lineage-defining transcription factors SOX2 and NKX2-1 determine lung cancer cell fate and shape the tumor immune microenvironment. Immunity. 2018;49(4):764–79.e9. doi:10.1016/j.immuni.2018.09.020.
   PubMed Web of Science ®Google Scholar
• Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 2016;76(5):999–1008. doi:10.1158/0008-5472.CAN-15-1439.
   PubMed Web of Science ®Google Scholar
• Maier B, Leader AM, Chen ST, Tung N, Chang C, LeBerichel J, Chudnovskiy A, Maskey S, Walker L, Finnigan JP, et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature. 2020;580(7802):257–262. doi:10.1038/s41586-020-2134-y.
   PubMed Web of Science ®Google Scholar
• Pfirschke C, Engblom C, Gungabeesoon J, Lin Y, Rickelt S, Zilionis R, Messemaker M, Siwicki M, Gerhard GM, Kohl A, et al. Tumor-promoting Ly-6G(+) SiglecF(high) cells are mature and long-lived Neutrophils. Cell Rep. 2020;32(12):108164. doi:10.1016/j.celrep.2020.108164.
   PubMed Web of Science ®Google Scholar
• Ancey PB, Contat C, Boivin G, Sabatino S, Pascual J, Zangger N, Perentes JY, Peters S, Abel ED, Kirsch DG, et al. GLUT1 expression in tumor-associated neutrophils promotes lung cancer growth and resistance to radiotherapy. Cancer Res. 2021;81(9):2345–2357. doi:10.1158/0008-5472.CAN-20-2870.
   PubMed Web of Science ®Google Scholar
• DuPage M, Cheung AF, Mazumdar C, Winslow MM, Bronson R, Schmidt LM, Crowley D, Chen J, Jacks T. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell. 2011;19(1):72–85. doi:10.1016/j.ccr.2010.11.011.
   PubMed Web of Science ®Google Scholar
• Caronni N, Piperno GM, Simoncello F, Romano O, Vodret S, Yanagihashi Y, Dress R, Dutertre C-A, Bugatti M, Bourdeley P, et al. TIM4 expression by dendritic cells mediates uptake of tumor-associated antigens and anti-tumor responses. Nat Commun. 2021;12(1):2237. doi:10.1038/s41467-021-22535-z.
   PubMed Web of Science ®Google Scholar
• Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485–498. doi:10.1038/s41577-020-00490-y.
   PubMed Web of Science ®Google Scholar
• Zhu J, Powis de Tenbossche CG, Cane S, Colau D, van Baren N, Lurquin C, Schmitt-Verhulst A-M, Liljeström P, Uyttenhove C, Van den Eynde BJ, et al. Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Nat Commun. 2017;8(1):1404. doi:10.1038/s41467-017-00784-1.
   PubMedGoogle Scholar
• Boivin G, Faget J, Ancey PB, Gkasti A, Mussard J, Engblom C, Pfirschke C, Contat C, Pascual J, Vazquez J, et al. Durable and controlled depletion of neutrophils in mice. Nat Commun. 2020;11(1):2762. doi:10.1038/s41467-020-16596-9.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337.
   PubMed Web of Science ®Google Scholar
• Deng J, Ma X, Ni Y, Li X, Xi W, Tian M, Zhang X, Xiang M, Deng W, Song C, et al. Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non-small cell lung cancer. Cancer Med. 2022. doi:10.1002/cam4.4567.
   Web of Science ®Google Scholar
• Kaltenmeier C, Yazdani HO, Morder K, Geller DA, Simmons RL, Tohme S. Neutrophil extracellular traps promote T cell exhaustion in the tumor microenvironment. Front Immunol. 2021;12:785222. doi:10.3389/fimmu.2021.785222.
   PubMed Web of Science ®Google Scholar
• Maier BB, Hladik A, Lakovits K, Korosec A, Martins R, Kral JB, Mesteri I, Strobl B, Müller M, Kalinke U, et al. Type I interferon promotes alveolar epithelial type II cell survival during pulmonary Streptococcus pneumoniae infection and sterile lung injury in mice. Eur J Immunol. 2016;46(9):2175–2186. doi:10.1002/eji.201546201.
   PubMed Web of Science ®Google Scholar
• Akbay EA, Koyama S, Liu Y, Dries R, Bufe LE, Silkes M, Alam MM, Magee DM, Jones R, Jinushi M, et al. Interleukin-17A promotes lung tumor progression through Neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade. J Thorac Oncol. 2017;12(8):1268–1279. doi:10.1016/j.jtho.2017.04.017.
   PubMed Web of Science ®Google Scholar
• Kowalczuk O, Burzykowski T, Niklinska WE, Kozlowski M, Chyczewski L, Niklinski J. CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. Tumour Biol. 2014;35(5):4619–4628. doi:10.1007/s13277-014-1605-x.
   PubMedGoogle Scholar
• Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2021. doi:10.1038/s41577-021-00574-3.
   PubMed Web of Science ®Google Scholar
• Ren F, Zhao T, Liu B, Pan L. Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB). Onco Targets Ther. 2019;12:4235–4244. doi:10.2147/OTT.S199176.
   PubMed Web of Science ®Google Scholar
• Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, Nefedova Y, Lin C, et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol. 2016;1(2). doi:10.1126/sciimmunol.aaf8943.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Li H, Deng Y, Tai Y, Zeng K, Zhang Y, Liu W, Zhang Q, Yang Y. Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death Dis. 2018;9(4):422. doi:10.1038/s41419-018-0458-4.
   PubMed Web of Science ®Google Scholar
• Dimitrova N, Gocheva V, Bhutkar A, Resnick R, Jong RM, Miller KM, Bendor J, Jacks T. Stromal expression of miR-143/145 promotes neoangiogenesis in lung cancer development. Cancer Discov. 2016;6(2):188–201. doi:10.1158/2159-8290.CD-15-0854.
   PubMed Web of Science ®Google Scholar
• Rustighi A, Zannini A, Tiberi L, Sommaggio R, Piazza S, Sorrentino G, Nuzzo S, Tuscano A, Eterno V, Benvenuti F, et al. Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med. 2014;6(1):99–119. doi:10.1002/emmm.201302909.
   PubMed Web of Science ®Google Scholar
• Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti A, Poletti A, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147(4):759–772. doi:10.1016/j.cell.2011.09.048.
   PubMed Web of Science ®Google Scholar
• Sturm G, Finotello F, Petitprez F, Zhang JD, Baumbach J, Fridman WH, List M, Aneichyk T. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 2019;35(14):i436–i45. doi:10.1093/bioinformatics/btz363.
   PubMed Web of Science ®Google Scholar
• Craven KE, Gokmen-Polar Y, Badve SS. CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. Sci Rep. 2021;11(1):4691. doi:10.1038/s41598-021-83913-7.
   PubMed Web of Science ®Google Scholar